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Compilations of key articles and guidelines in a particular clinical practice
area are useful not only to clinicians who practice in that area, but to all
clinicians.  We compiled pertinent articles and guidelines pertaining to drug
therapy in the intensive care setting from the perspective of actively practicing
critical care pharmacists.  This document differs from the original 2002
version in that a broader assembly of intensive care practitioners was involved
in the compilation.
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The original compilation of key articles and
guidelines pertaining to intensive care unit (ICU)
pharmacology was published in 2002 (Pharmaco-
therapy 22;12:1594–610).  That compilation was
primarily from the perspective of the general ICU
practice of the primary author (BLE); therefore,
certain topics (e.g., stroke) were not covered to a
significant degree.  This document was compiled
by selected members of the Critical Care Practice
and Research Network (PRN) of the American
College of Clinical Pharmacy. Therefore, this
bibliography contains a more diverse range of
articles reflective of the authors’ interest areas
and practice settings.  In addition, we compiled
this version using an evidence-based classification
system for research investigations (Eastern
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Association for the Surgery of Trauma [EAST] Ad
Hoc Committee on Practice Management
Guideline Development.  Utilizing evidence-
based outcome measures to develop practice
management guidelines:  a primer; available from
http://www. east.org/tpg.html).  This classifi-
cation system is as follows:  class I, randomized
controlled trials; class II, prospective trials and
retrospective studies with reliable data (e.g., case-
control studies); and class III, retrospective
studies and expert opinion.
The information in this compilation should be
particularly useful for trainees and relatively new
practitioners in the critical care setting.  However,
we hope it also might serve as a useful template
for experienced clinicians who have contemplated
a similar undertaking in their practice areas.
The development process began with a
preliminary discussion of a potential revision of
the original article by several Critical Care PRN
members.  These members were subsequently
sent a copy of the original article and asked for
input regarding possible format changes (e.g.,
disease- vs drug-based approach) and choice of
sections for authorship.  Additional authors from
the Critical Care PRN were then invited to
participate based on their recognized areas of
expertise in sections not chosen by members of
the initial group.  Once written, the sections were
compiled and reviewed by all authors to help
ensure appropriate article selections and
summaries.  We could not include every published
paper we considered important to critical care
pharmacotherapy; however, we compiled what
we believed were the most representative articles
addressing the selected critical care topics.
As in the original version, this bibliography is
divided into three general sections.  The first
focuses on landmark and contemporary pivotal
articles and guidelines pertaining to pharmaco-
therapy in the ICU setting.  When these were not
available in a specific clinical area, comprehensive
reviews or articles were chosen that have
generated substantial discussion among ICU
practitioners.  The second section focuses on
literature pertaining to the economic justification
of ICU pharmacy services (both supporting and
opposing) or, more specifically, the justification
of pharmacists in the critical care setting.  The
final section focuses on articles pertaining to
medication errors and adverse drug events in the
ICU.  Many of the articles pertaining to adverse
drug events in the institutional setting apply to
the ICU, but we chose articles specific to the ICU.
Pharmacotherapy in the Intensive Care Unit
Acid-Base Disorders
Gehlbach BK, Schmidt GA. Bench-to-bedside
review: treating acid-base abnormalities in the
intensive care unit: the role of buffers. Crit Care
2004;8:259–65.
This article reviews the pharmacologic
buffering therapy available to treat metabolic
acidosis in the ICU.  The agents reviewed include
sodium bicarbonate, Carbicarb (an equimolar
solution of sodium bicarbonate and sodium
carbonate), tromethamine, dichloroacetate,
thiamine, and volume expanders.  Evidence for
the clinical efficacy of these buffering agents and
correction of arterial pH are also reviewed.
Kellum JA. Determinants of blood pH in health
and disease. Crit Care 2000;4:6–14.
The practice of critical care requires an
advanced understanding of acid-base physiology.
This article reviews three variables that regulate
blood pH:  carbon dioxide, relative electrolyte
concentrations, and total weak acid concentra-
tions.  It provides pathophysiologic mechanisms
by organ system and differential diagnoses of
metabolic acid-base disorders.
Adrogue HJ, Madias NE. Management of life-
threatening acid-base disorders: part I. N Engl J
Med 1998;338:26–34.
This is the first of a two-part review article that
focuses on consequences of severe acidemia.  It
reviews the management of metabolic acidosis
(lactic acidosis, diabetic ketoacidosis, alcoholic
ketoacidosis, methanol and ethylene glycol
intoxications, aspirin intoxication, toluene
exposure, bicarbonate loss, renal failure and
dilutional acidosis) and respiratory acidosis.
Adrogue HJ, Madias NE. Management of life-
threatening acid-base disorders: part II. N Engl J
Med 1998;338:107–11.
Part II of the two-part article reviews the
adverse cardiovascular, respiratory, metabolic and
cerebral consequences of severe alkalemia.
Management strategies for metabolic alkalosis,
respiratory alkalosis, pseudorespiratory alkalosis,
and mixed alkaloses are discussed.
Acute Respiratory Distress Syndrome
Ware LB, Matthay MA. The acute respiratory
distress syndrome. N Engl J Med 2000;342:
1334–49.
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In recent years, advances have been made in
the treatment and general understanding of acute
respiratory distress syndrome.  This compre-
hensive review article addresses the definitions,
epidemiology, pathogenesis, and treatment of the
syndrome.  The authors concluded that future
trials targeting new ventilatory strategies or
pharmacotherapy may further demonstrate a
reduction in mortality.
The Acute Respiratory Distress Syndrome
(ARDS) Network Authors. Ketoconazole for
early treatment of acute lung injury and acute
respiratory distress syndrome: a randomized
controlled trial. JAMA 2000;283:1995–2002.
Ketoconazole possesses antiinflammatory
properties that may be beneficial for the
treatment or prevention of early acute lung injury
or acute respiratory distress syndrome.  In this
randomized controlled trial, no significant
differences in survival, duration of mechanical
ventilation, or lung function were found between
ketoconazole 400 mg/day (117 patients) and
placebo (117 patients).  This article is important
because it provided firm evidence that keto-
conazole is not useful for treatment of acute
respiratory distress syndrome.  (Class I)
Alcohol Withdrawal
Dappen JB, Gache P, Landry U, et al. Symptom-
triggered versus fixed-schedule doses of
benzodiazepine for alcohol withdrawal: a
randomized treatment trial. Arch Intern Med
2002;162:1117–21.
This randomized, double-blind, controlled trial
evaluated the potential benefits of individualized
therapy compared with fixed-schedule dosing of
benzodiazepine for prevention of alcohol
withdrawal.  Benzodiazepine therapy was
administered either as a fixed dose or based on
the patient’s score on the revised Clinical
Institute Withdrawal Assessment–Alcohol, using
a placebo-controlled, double-dummy design.
Symptom-triggered therapy resulted in a
significant reduction in dosage and duration of
therapy compared with the fixed-dosage regimen.
The authors concluded that symptom-triggered
therapy can shorten detoxification time and
reduce unnecessary drug administration without
compromising safety.  The ability to extrapolate
these findings to critically ill patients
experiencing alcohol withdrawal is unknown.
(Class I)
D’Onofrio G, Rathlev NK, Ulrich AS, Fish SS,
Freedland ES. Lorazepam for the prevention of
recurrent seizures related to alcohol. N Engl J
Med 1999;340:915–19.
This prospective, randomized, double-blind,
placebo-controlled trial evaluated whether
lorazepam prevented recurrent seizures in
chronic alcoholics.  One hundred eighty-six
patients with a witnessed generalized seizure,
known to have had a drink within 72 hours of
seizure onset, received either lorazepam or
placebo in addition to routine care.  Patients were
observed for 6 hours for evidence of recurrent
alcohol-related seizures.  The risk of subsequent
seizures was significantly higher in the placebo
group (odds ratio [OR] 10.4, 95% confidence
interval [CI] 3.6–30.2).  Based on these findings,
benzodiazepines appear to be effective agents for
the prevention of recurrent alcohol withdrawal
seizures.  (Class I)
Mayo-Smith MF, for the American Society of
Addiction Medicine Working Group on
Pharmacological Management of Alcohol
Withdrawal. Pharmacological management of
alcohol withdrawal: a meta-analysis and evidence-
based practice guideline. JAMA 1997;278:144–51.
This article presents an evidence-based
guideline for the pharmacologic management of
alcohol withdrawal based on a meta-analysis of
the literature.  Six prospective, controlled trials,
involving five different agents, demonstrated that
benzodiazepines are the most efficacious drug
therapy for reducing signs and symptoms of
alcohol withdrawal.  The superiority of one
benzodiazepine over another was not definitively
demonstrated.  The use of a structured assessment,
such as the revised Clinical Institute Withdrawal
Assessment–Alcohol, is recommended for
evaluating and monitoring patients at risk for
alcohol withdrawal.  Treatment guidelines and a
discussion regarding the efficacy of potential
adjunctive options are provided.  This guideline
did not specifically address the management of
alcohol withdrawal in critically ill patients.
Cardiovascular
The following compilations of key articles and
guidelines pertaining to arrhythmias, acute
coronary syndromes, and hypertension have been
covered in previous issues of this journal:
Dobesh PP, Brouse SD, Johnson DC, et al. Key
articles and guidelines relative to treatment of
patients with acute coronary syndromes.
Pharmacotherapy 2004;24:105–44.
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Cheng JW, Frank L, Garrett SD, Lu Y, Sanoski
CA, White CM. Key articles and guidelines in
pharmacotherapeutic management of arrhythmias.
Pharmacotherapy 2004;24:248–79.
de Denus S, Hardy AM, Olson KL, Robinette B.
Key articles and guidelines in the management of
hypertension. Pharmacotherapy 2004;24:1385–99.
Arrhythmias
Karth GD, Geppert A, Neunteufl T, et al.
Amiodarone versus diltiazem for rate control in
critically ill patients with atrial tachyarrhythmias.
Crit Care Med 2001;29:1149–53.
Atrial arrhythmias are common in critically ill
patients.  In this prospective, randomized trial,
two different dosage regimens of amiodarone
were compared with diltiazem in 60 patients with
new-onset atrial tachyarrhythmias (95% had
atrial fibrillation).  At least 50% of patients in all
three groups achieved more than a 30% rate
reduction within 4 hours (p=NS).  Over a 24-
hour period, patients receiving diltiazem
demonstrated a significantly greater reduction in
heart rate than those in either amiodarone group
(p<0.01).  However, frequency of hypotension
was higher in the diltiazem group (p<0.01), often
requiring withdrawal of treatment.  The authors
concluded that both drugs provided effective rate
control in patients with atrial tachyarrhythmias;
however, amiodarone may be better tolerated in
hemodynamically unstable patients.  (Class I)
Hughes M, Binning A. Intravenous amiodarone
in intensive care: time for a reappraisal? Intensive
Care Med 2000;26:1730–9.
The authors cite drug-induced acute pulmonary
toxicity in critically ill patients as a reason to
reevaluate the use of amiodarone in the ICU.
This article reviews dosing, pharmaco-dynamics,
pharmacokinetics, drug interactions, efficacy, and
toxicity of amiodarone.  The authors concluded
that there are alternatives to amiodarone for
many patients, and caution should be exercised
when the drug is used in the treatment of critically
ill patients.
Heart Failure
Publication Committee for the VMAC Investi-
gators. Intravenous nesiritide vs nitroglycerin for
the treatment of decompensated congestive heart
failure: a randomized controlled trial. JAMA
2002;287:1531–40.
The Vasodilation in the Management of Acute
Congestive Heart Failure (VMAC) trial enrolled
489 patients with New York Heart Association
class III or IV heart failure at 55 medical centers
in the United States.  The primary end points
were changes in pulmonary capillary wedge
pressure (PCWP) and patient-reported dyspnea
scores at 3 hours.  Secondary outcome measures
were PCWP changes at 24 hours, dyspnea scores,
global clinical status, and safety.  Patients were
initially stratified based on presence or absence of
a right heart catheter.  At the end of 3 hours, the
mean change in PCWP was -5.8 mm Hg for
patients receiving nesiritide, -3.8 mm Hg for
those receiving nitroglycerin, and -2 mm Hg for
those receiving placebo (p<0.05 for comparison
of nesiritide with nitroglycerin and placebo).
Dyspnea scores were significantly improved
when nesiritide was compared with placebo but
was no different when compared with nitro-
glycerin.  Global clinical status was similar in all
groups (p=NS).  After 24 hours, PCWP changed
by -8.2 mm Hg in the nesiritide group compared
with -6.3 mm Hg in the nitroglycerin group
(p=0.04).  Dyspnea and global clinical status
were not significantly different.  Adverse events
were more common in the nitroglycerin group
than the nesiritide group (p<0.001).  Headache
and pain were reported most often.  Rates of
hypotension, ischemic events, and arrhythmias
were similar between the groups.  However,
duration of hypotension was significantly longer
with nesiritide (2.2 hrs) than nitroglycerin (0.7
hrs) (p=0.002).  This trial provides additional
evidence for the conclusions of a previous trial
(see Colucci WS, Elkayam U, Horton DP, et al.
Intravenous nesiritide, a natriuretic peptide, in
the treatment of decompensated congestive heart
failure. N Engl J Med 2000;343:246–53) that
nesiritide is a useful addition to standard therapy
in the treatment of patients with decompensated
heart failure.  (Class I)
Heart Failure Society of America. Heart Failure
Society of America (HFSA) practice guidelines.
HFSA guidelines for management of patients
with heart failure caused by left ventricular
systolic dysfunction—pharmacological approaches.
J Card Fail 1999;5:357–82.
These guidelines present a graded, evidence-
based approach to managing heart failure.  They
provide an overview of public health concerns,
pathophysiology, and therapy.  The guidelines
consider angiotensin-converting enzyme inhibitors
and diuretics fundamental aspects of heart failure
treatment.  Graded recommendations are made
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for adding adrenergic receptor blockers, digoxin,
anticoagulation and antiplatelet agents,
angiotensin receptor blockers, antiarrhythmics,
and aldosterone antagonists.  Treatment of
myocarditis is also reviewed.
Hypertension
Haas CE, LeBlanc JM. Acute postoperative
hypertension: a review of therapeutic options.
Am J Health-Syst Pharm 2004;61:1661–75.
This article reviews the underlying patho-
physiology, hemodynamics, potential compli-
cations, and treatment options for acute
postoperative hypertension.  The authors present
the pharmacology, clinical response, and
supporting evidence for the vasodilators and b-
blockers commonly used in the management of
acute postoperative hypertension, along with the
significant limitations of the current literature.
Fluids
The SAFE Study Investigators. A comparison of
albumin and saline for fluid resuscitation in the
intensive care unit. N Engl J Med 2004;350:
2247–56.
This multicenter, randomized, double-blind
comparison of 4% albumin and normal saline for
resuscitation of patients admitted to the ICU
enrolled 6997 patients; 28-day mortality was the
primary end point.  No statistically significant
differences were observed in death (relative risk
[RR] 0.99, 95% CI 0.91–1.09) or any of the
secondary end points under study.  (Class I)
Cooper DJ, Myles PS, McDermott FT, et al.
Prehospital hypertonic saline resuscitation of
patients with hypotension and severe traumatic
brain injury. JAMA 2004;291:1350–7.
This was a double-blind, randomized, controlled
trial involving 229 hypotensive patients (systolic
blood pressure < 100 mm Hg) who experienced
traumatic brain injury (Glasgow Coma Scale
score < 9).  In addition to conventional resusci-
tation procedures employed by paramedics,
patients were randomized to receive rapid
intravenous infusions (250 ml) of either 7.5%
sodium chloride or Ringer’s lactate solution.
Patients in both groups were given additional
crystalloid or colloid fluids based on protocol.
The major outcome measure was the extended
Glasgow Outcome Score at 6 months.  Survival
rates were similar with 7.5% sodium chloride and
Ringer’s lactate (55% and 50%, respectively, at
discharge, p=0.32; 55% and 47%, respectively, at
6 mo, p=0.23).  Similarly, no significant difference
was noted between the groups based on
neurologic function (p=0.96).  The use of the
Glasgow Outcome Score as a primary outcome
measure in this study is somewhat of a concern
in that it is more reflective of unfavorable rather
than favorable outcomes.  However, as mentioned
by the investigators in their response to this
criticism (JAMA 2004;291:2944–5), a much
larger sample would have been needed to
investigate the effects of the solutions based on a
favorable outcome measure.  (Class I)
Sort P, Navasa M, Arroyo V, et al. Effect of intra-
venous albumin on renal impairment and
mortality in patients with cirrhosis and spon-
taneous bacterial peritonitis. N Engl J Med
1999;341:403–9.
Renal impairment, as a result of cytokine
release and decreased arterial blood volume, is
common in patients with spontaneous bacterial
peritonitis.  Albumin may prevent renal dys-
function through its effects on volume expansion
and possibly other mechanisms.  In this study,
126 patients with cirrhosis and spontaneous
bacterial peritonitis were randomized to cefo-
taxime or cefotaxime plus albumin.  In the
control group, 33% of patients developed renal
impairment, versus 10% in the albumin group
(p=0.002).  Mortality in the hospital and at 3
months was significantly lower in albumin-
treated patients than in control patients (p=0.01
and p=0.03, respectively).  This trial is important
because it is one of the few well-controlled trials
demonstrating a positive benefit of albumin beyond
its effects on surrogate end points.  (Class I)
Choi PTL, Yip G, Quinonez LG, Cook DJ.
Crystalloids vs. colloids in fluid resuscitation: a
systematic review. Crit Care Med 1999;27:
200–10.
This review of 17 randomized trials compared
isotonic crystalloids with colloids for volume
resuscitation in 814 adult patients.  No differences
were noted in mortality, pulmonary edema, or
length of hospital stay. However, a subgroup
analysis revealed decreased mortality with
crystalloid administration in patients who
experienced trauma (RR 0.39, 95% CI 0.17–0.89).
The authors concluded that more research is
necessary to resolve the ongoing controversy
regarding the most appropriate and effective
method for fluid resuscitation.
Cochrane Injuries Group Albumin Reviewers.
Human albumin administration in critically ill
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patients: systematic review of randomised
controlled trials. BMJ 1998;317:235–40.
In this systematic review of 30 randomized,
controlled trials involving 1419 critically ill
patients, albumin administration was associated
with one death for every 17 patients treated for
hypovolemia, burns, or hypoalbuminemia.
Although a significant difference in mortality
after albumin administration was not found in
each of the categories, the pooled relative risk of
albumin-associated death was significant (RR
1.68, 95% CI 1.26–2.23).  This review, as well as
an earlier review in the same journal (Schierhout
G, Roberts I. Fluid resuscitation with colloid or
crystalloid solutions in critically ill patients: a
systematic review of randomised trials. BMJ
1998;316:961–4), fueled the colloid-crystalloid
debate by pushing the limits of meta-analytic
technique.
Bickell WH, Wall MJ, Pepe PE, et al. Immediate
versus delayed fluid resuscitation for hypotensive
patients with penetrating torso injuries. N Engl J
Med 1994;331:1105–9.
Previous studies in animal models have
suggested that the volume of intravenous fluid
resuscitation may contribute to intraoperative
bleeding.  In this prospective study, trauma
patients with hypotension were randomized to
immediate (309 patients) or delayed (289
patients) resuscitation.  The primary objective
was to determine if the rate of survival would
improve when intravenous fluid resuscitation
was withheld until the time of surgery.  The
overall rate of survival was significant in the
delayed versus immediate resuscitation group
(70% vs 62%, p=0.04).  Postoperative complica-
tions (acute respiratory distress syndrome, sepsis
syndrome, acute renal failure, coagulopathy,
wound infection, and pneumonia) also tended to
occur less often when fluid administration was
delayed, although the difference was not
significant.  (Class I)
Endocrine Conditions
Hamrahian AH, Oseni TS, Arafah BM.
Measurements of serum free cortisol in critically
ill patients. N Engl J Med 2004;350:1629–38.
This prospective study assessed baseline serum
total cortisol, cosyntropin-stimulated serum total
cortisol, aldosterone, and free cortisol concen-
trations in 60 critically ill patients and 33 healthy
volunteers.  Critically ill patients were stratified
into two groups based on serum albumin
concentration.  Baseline and cosyntropin-
stimulated total cortisol concentrations were
significantly lower in patients whose albumin
concentrations were 2.5 g/dl or less.  However,
average baseline free cortisol concentrations were
not different between the two groups of critically
ill patients.  Free cortisol concentrations were
more than 8 times higher in the critically ill
patients than in the healthy volunteers.  The
authors concluded that caution should be used in
interpreting total cortisol concentrations in
critically ill patients with hypoalbuminemia, and
that measuring serum free cortisol concentrations
may prevent unnecessary use of glucocorticoids.
(Class II)
Van den Berghe G, Wouters PJ, Bouillon R, et
al. Outcome benefit of intensive insulin therapy
in the critically ill: insulin dose versus glycemic
control. Crit Care Med 2003;31:359–66.
This is a secondary analysis of a previously
published report demonstrating the efficacy of
intensive insulin therapy in reducing morbidity
and mortality among critically ill patients.  The
authors focused their assessment on the
feasibility and safety of intensive insulin therapy,
identification of factors that determine insulin
requirements, and determination of the impact of
glycemic control versus the amount of exogenous
insulin infused on morbidity and mortality
measures.  The analysis demonstrated that it is
safe and feasible to maintain blood glucose levels
of 80–110 mg/dl using a titration algorithm.
Independent factors influencing insulin
requirements were body mass index, history of
diabetes mellitus, reason for ICU admission,
presence of hyperglycemia on admission, caloric
intake, and duration of ICU stay.  Multivariate
logistic regression analysis revealed that lower
blood glucose level rather than insulin dosage
was related to reduced morbidity and mortality.
Among patients whose ICU stay exceeded 5 days,
post hoc analysis revealed a gradual decrease in
risk of death with decreasing blood glucose level.
Patients whose blood glucose was maintained at
intermediate levels of 110–150 mg/dl had worse
outcomes than those whose levels were normal.
(Class II)
Cooper MS, Stewart PM. Corticosteroid insuffi-
ciency in acutely ill patients. N Engl J Med
2003;348:727–34.
This review eloquently summarizes the
physiology of corticosteroid response to acute
illness by contrasting both the appropriate and
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inappropriate hypothalamic-pituitary-adrenal
axis response during acute illness.  The authors
describe the clinical features of hypoadrenalism
in patients with acute illness.  They also provide
a useful algorithm for evaluating adrenal cortico-
steroid function in critically ill patients based on
random cortisol levels and/or the corticotropin
stimulation test.  Recommendations are provided
for steroid replacement during acute illness in
patients with adrenal insufficiency, including
those who previously received corticosteroids.
Van den Berghe G, Wouters P, Weekers F, et al.
Intensive insulin therapy in critically ill patients.
N Engl J Med 2001;345:1359–67.
This prospective, randomized, controlled trial
involving 1548 mechanically ventilated surgical
patients with hyperglycemia evaluated the effects
of intensive insulin therapy or conventional
treatment.  Goal blood glucose levels were
80–110 mg/dl with intensive insulin therapy and
180–200 mg/dl with conventional treatment.  At
12 months, mortality was significantly reduced in
the intensive insulin therapy group compared
with the conventional treatment group (4.6% vs
8%, p<0.04).  The benefits of intensive insulin
therapy were most noteworthy in the patients
whose ICU stay exceeded 5 days; mortality was
10.6% in that intensive insulin therapy group
compared with 20.2% in the conventional
treatment group (p<0.005).  This trial also
demonstrated significant reductions in morbidity
(e.g., bloodstream infections, acute renal failure
requiring dialysis, number of blood transfusions,
critical-illness polyneuropathy, duration of
mechanical ventilation, and length of ICU stay)
with the use of intensive insulin therapy.  (Class I)
Singer I, Oster JR, Fishman LM. The manage-
ment of diabetes insipidus in adults. Arch Intern
Med 1997;157:1293–301.
This comprehensive review discusses the
pathogenesis, differential diagnosis, and treat-
ment strategies for acute and chronic water
deficits.  Desmopressin acetate is the preferred
agent for treatment of symptomatic central dia-
betes insipidus, whereas treatment of nephro-
genic diabetes insipidus centers on the resolution
of underlying conditions.  The authors identified
noncompliance, medical emergency, and
iatrogenic inadvertence as the most common
causes of unplanned treatment withdrawals.
Fever
Henker R. Evidence-based practice: fever-related
interventions. Am J Crit Care 1999;8:481–9.
This review summarizes the literature regarding
whether or not a fever should be treated and the
effectiveness of various interventions for treating
fever in critically ill patients.  Although the
author does not use the more traditional classifi-
cations of levels of evidence, in which level 1 is
the highest, the classification used is provided
and readily understandable.  The review highlights
the tremendous lack of data evaluating various
strategies (e.g., physical cooling vs antipyretics)
used to treat fever.
O’Grady NP, Barie PS, Bartlett J, et al. Practice
parameters for evaluating new fever in critically
ill adult patients. Crit Care Med 1998;26:392–408.
Fever in intensive care patients consumes
substantial financial and medical resources.  An
interdisciplinary team with members from the
areas of critical care, infectious diseases, and
surgery developed consensus guidelines to aid in
the rational, cost-conscious evaluation of a new
fever.  The overall aim of these evidence-based
guidelines, endorsed by the Society of Critical
Care Medicine and the Infectious Diseases
Society of America, is to minimize unnecessary




Meissner W, Dohrn B, Reinhart K. Enteral
naloxone reduces gastric tube reflux and
frequency of pneumonia in critical care patients
during opioid analgesia. Crit Care Med
2003;31:776–80.
This prospective, randomized, double-blind
trial evaluated the efficacy of enteral naloxone (8
mg every 6 hrs) versus placebo in reducing
gastric tube reflux and the frequency of
pneumonia in 84 mechanically ventilated
patients.  All patients were receiving continuous
infusion of fentanyl for analgesia, and the dosage
requirements were not significantly different
between the two groups.  The median daily
gastric tube reflux volumes were significantly
lower in the naloxone treatment group than in
the placebo group (54 vs 129 ml, p=0.03).  The
frequency of pneumonia was also significantly
lower in the naloxone versus the placebo group
(34.2% vs 55.8%, p=0.04).  The authors concluded
that oral naloxone might be a simple and
possibly preventive strategy to reduce gastric
tube reflux and the frequency of pneumonia in
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fentanyl-treated, mechanically ventilated
patients.  (Class I)
Booth CM, Heyland DK, Peterson WG.
Gastrointestinal promotility drugs in the critical
care setting: a systematic review of the evidence.
Crit Care Med 2002;30:1429–35.
Delayed gastric emptying is common among
critically ill patients, occurring in up to 60% of
those who are mechanically ventilated.  Gastric
hypomotility may lead to impaired nutrient
delivery, high gastric residuals, and risk of
aspiration.  This review summarizes the data
regarding the efficacy of prokinetic agents
(metoclopramide, erythromycin, and cisapride)
in improving gastric emptying in critically ill
patients.  Eight of the 10 studies reviewed
demonstrated a positive effect.  However, four of
these studies evaluated only cisapride, which has
been removed from the United States market.
Although evidence supports the efficacy of
prokinetic agents (erythromycin and metoclo-
pramide) for promoting gastric emptying, data
demonstrating a positive impact on patient
outcome (e.g., reduced frequency of pneumonia
or mortality) are lacking.
van der Spoel J, Oudemans-van Straaten H,
Stoutenbeek C, Bosman R, Zandstra D.
Neostigmine resolves critical illness–related
colonic ileus in intensive care patients with
multiple organ failure—a prospective, double-
blind, placebo-controlled trial. Intensive Care
Med 2001;27:822–7.
In this double-blind, randomized, placebo-
controlled trial of 30 ventilated patients with
multiple organ failure, 11 of 13 responded to
neostigmine treatment for critical illness–related
colonic ileus; resolution of symptoms was not
evident in any of the patients in the placebo
group (11 neostigmine-treated patients vs 0
placebo patients, p<0.001).  Nineteen (79%) of
24 neostigmine-treated patients defecated,
including nonresponders who were switched
from the placebo group.  Continuous infusion of
neostigmine (0.4–0.8 mg/hr for 24 hrs) appeared
to be a well-tolerated therapy in this small
sample of critically ill, mechanically ventilated
patients with a colonic ileus.  (Class I)
Stress Ulcer Prophylaxis
Cook DJ, Griffith LE, Walter SD, et al. The
attributable mortality and length of intensive care
unit stay of clinically important gastrointestinal
bleeding in critically ill patients. Crit Care
2001;5:368–75.
This study uses three different strategies to
estimate mortality and length of stay in the ICU
attributable to clinically important upper
gastrointestinal bleeding.  Data from 1666
mechanically ventilated patients from two
multicenter databases were used to perform the
analyses.  Of the 1666 patients, 59 developed
clinically important gastrointestinal bleeding.
Risk of death was increased in patients with
bleeding, regardless of analysis strategy used;
relative risk ranged from 1.8 (95% CI 1.1–2.9) to
4.1 (95% CI 2.6–6.5).  The median length of ICU
stay attributable to clinically important bleeding
was 3.8–7.9 days depending on the model
employed.  Overall, this study demonstrates that
although the frequency of clinically important
gastrointestinal bleeding may be low, the patient’s
condition is associated with important attrib-
utable morbidity, such as a long ICU stay (4–8
days), and mortality.  (Class II)
American Society of Health-System Pharmacists.
ASHP therapeutic guidelines on stress ulcer
prophylaxis. Am J Health-Syst Pharm 1999;56:
347–79.
Numerous articles have been published on
stress ulcer prophylaxis.  This comprehensive,
evidence-based guideline reviews the frequency
of bleeding and the efficacy of prophylaxis in
intensive care patients and special populations.
Although this 1999 review lacks the more recent
findings, it summarizes the epidemiology and
populations at risk for stress ulcers.  It also
evaluates the evidence regarding treatment
options available at the time.  A more recent
article (Allen ME, Kopp BJ, Erstad BL. Am J
Health-Syst Pharm 2004;61:588–96) critically
reviews more recently published data on thera-
peutic approaches to stress ulcer prophylaxis.
Cook D, Guyatt G, Marshall J, et al. A compar-
ison of sucralfate and ranitidine for the preven-
tion of upper gastrointestinal bleeding in patients
requiring mechanical ventilation. N Engl J Med
1998;338:791–7.
Two agents used for stress ulcer prophylaxis,
ranitidine and sucralfate, were compared in 1200
mechanically ventilated, critically ill patients for
prevention of clinically important upper
gastrointestinal bleeding.  This landmark,
multicenter, randomized, double-blind, placebo-
controlled study demonstrated a lower bleeding
frequency in the ranitidine group than in the
sucralfate group (RR 0.44, 95% CI 0.21–0.92).
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No difference between the two groups was noted
for rate of ventilator-associated pneumonia,
length of ICU stay, or survival.  This study
demonstrates the superiority of ranitidine (50 mg
given intravenously every 8 hrs) over sucralfate
(1 g administered by nasogastric tube every 6
hrs) for prevention of clinically important upper
gastrointestinal bleeding.  (Class I)
Cook DJ, Fuller HD, Guyatt GH, et al. Risk
factors for gastrointestinal bleeding in critically
ill patients. N Engl J Med 1994;330:377–81.
This prospective, multicenter, observational
study evaluated potential risk factors for stress
ulceration in 2252 critically ill patients.
Clinically important gastrointestinal bleeding
occurred in 1.5% of patients.  The two major
independent risk factors for bleeding identified
by multivariate analyses were respiratory failure
(OR 15.6), and coagulopathy (OR 4.3).  This
study clearly highlights the importance of
respiratory failure and coagulopathy as two major
risk factors for stress-related mucosal bleeding.
However, because the study involved only a
critically ill patient population, these should not
be considered the only risk factors for stress-
related mucosal bleeding.  Specifically, earlier
literature suggests that patients with head injury,
burns, multiple trauma, sepsis, or shock may also
be at risk.  However, few patients with these
conditions were included in the trial.  (Class II)
Nonvariceal Upper Gastrointestinal Bleeding
Barkun A, Bardou M, Marshall JK, et al.
Consensus recommendations for managing
patients with nonvariceal upper gastrointestinal
bleeding. Ann Intern Med 2003;139:843–57.
Consensus guidelines for the management of
nonvariceal upper gastrointestinal bleeding were
developed by a multidisciplinary panel repre-
senting 11 national societies.  The guidelines
recommend that institution-specific protocols be
developed.  Initial management should include
stratification of patients into high and low risk
categories for rebleeding and death on the basis
of clinical, endoscopic, and prognostic factors.
Early endoscopy is warranted to facilitate
diagnosis and risk stratification, and to provide
hemostasis in patients with stigmata suggesting
high risk of rebleeding.  A combination of
injection and thermal coagulation provides
superior endoscopic hemostasis in patients with
high-risk stigmata compared with either
treatment alone.  High-dose intravenous therapy
with a proton pump inhibitor is recommended
for patients who have undergone endoscopic
hemostasis.  Each recommendation was graded
according to the level and strength of available
evidence.
Sung JJY, Chan FKL, Lau JYW, et al. The effect
of endoscopic therapy in patients receiving
omeprazole for bleeding ulcers with nonbleeding
visible vessels or adherent clots. Ann Intern Med
2003;139:237–43.
Earlier trials demonstrated that omeprazole
given as a continuous infusion is effective in
preventing peptic ulcer rebleeding in patients at
high risk of rebleeding (i.e., nonbleeding visible
vessel or bleeding ulcers) who have undergone
endoscopic hemostasis.  This single-blind,
randomized trial assessed whether combination
therapy (endoscopy plus a proton pump
inhibitor) was superior to omeprazole alone in
preventing peptic ulcer rebleeding in patients
with nonbleeding visible vessels or adherent
clots.  The probability of recurrent bleeding
within 30 days was significantly less in the group
receiving combination therapy (1.1%) than in the
group receiving omeprazole alone (11.6%;
p=0.009).  Previously published data demon-
strating the efficacy of omeprazole after
endoscopic hemostasis, in concert with the
results of this study, emphasize that dual-
modality therapy (endoscopic hemostasis plus
intravenous omeprazole) is the most effective
strategy for reducing the risk of rebleeding in
high-risk patients.  (Class I)
Levine JE, Leontiadis GI, Sharma VK, Howden
CW. Meta-analysis: the efficacy of intravenous
H2-receptor antagonists in bleeding peptic ulcer.
Aliment Pharmacol Ther 2002;16:1137–42.
This meta-analysis was conducted to assess the
efficacy of histamine2 (H2)-receptor antagonists
in the management of peptic ulcer bleeding.
Pooling data from randomized placebo-
controlled trials, the authors demonstrated that
H2-receptor antagonists do not significantly
reduce rebleeding, surgery, or death in patients
with bleeding duodenal ulcers.  Significant,
however minor, reductions were observed in
rebleeding, surgery, and death in patients with
bleeding gastric ulcers (absolute risk reduction
7.2%, 6.7%, and 3.2%, respectively).  Based on
these data, intravenous H2-receptor antagonists
should be considered of no value in patients with
bleeding duodenal ulcers and of limited value in
patients with bleeding gastric ulcers.
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Gisbert JP, Gonzalez L, Clvert X, et al. Proton
pump inhibitors versus H2 antagonists: a meta-
analysis of their efficacy in treating bleeding
peptic ulcer. Aliment Pharmacol Ther 2001;15:
917–26.
This meta-analysis evaluated whether proton
pump inhibitors were more effective than H2-
receptor antagonists in patients with bleeding
peptic ulcers.  Using data from 11 international
comparative, randomized trials, persistent or
recurrent bleeding was noted in 6.7% (95% CI
4.9–8.6%) of patients receiving proton pump
inhibitors and in 13.4% (95% CI 10.8–16%) of
patients treated with H2-receptor antagonists.
Although this analysis demonstrates that proton
pump inhibitors are more effective than H2-
receptor antagonists in preventing persistent or
recurrent peptic ulcer bleeding, no significant
difference was seen in mortality or need for
surgery.
Lau JYW, Sung JJY, Lee KKC, et al. Effect of
intravenous omeprazole on recurrent bleeding
after endoscopic treatment of bleeding peptic
ulcers. N Engl J Med 2000;343:310–16.
This landmark, single-center, randomized,
double-blind, placebo-controlled trial assessed
the efficacy of intravenous omeprazole in
preventing peptic ulcer rebleeding after
endoscopic hemostasis.  Patients with actively
bleeding ulcers or ulcers with nonbleeding
visible vessels received endoscopic hemostasis
with epinephrine injection followed by thermo-
coagulation.  Then, 240 patients were random-
ized in a double-blind fashion to receive an intra-
venous bolus dose of omeprazole 80 mg followed
by 8 mg/hour continuous infusion, or placebo for
72 hours.  Subsequently, all patients received oral
omeprazole 20 mg/day for 8 weeks.  The
frequency of rebleeding within the first 30 days
was significantly reduced in the omeprazole
group (6.7%) compared with the placebo group
(22.5%).  Most episodes of bleeding occurred
within the first 3 days.  This well-designed trial
demonstrates the efficacy of omeprazole given as
a high-dose continuous infusion for prevention
of peptic ulcer rebleeding after endoscopic hemo-
stasis in patients at high risk of rebleeding.  (Class I)
Hematology
Antithrombotics
American College of Chest Physicians. The
seventh ACCP consensus conference on anti-
thrombotic and thrombolytic therapy: evidence-
based guidelines. Chest 2004;126(suppl):
163S–696.
This report from the American College of
Chest Physicians provides an extensive evidence-
based review of the management of thrombo-
embolic disorders.
Blood Conservation and Transfusion
Corwin HL, Gettinger A, Pearl RG, et al. The
CRIT study: anemia and blood transfusion in the
critically ill—current clinical practice in the
United States. Crit Care Med 2004:32:39–52.
This prospective, multicenter, observational,
cohort study of 4892 patients, conducted in
2000–2001, serves as an important historic
control to compare current patterns of blood use.
The patients’ mean ± SD hemoglobin level was 11
± 2.4 g/dl, with a progressive decrease through-
out the ICU stay.  Overall, 44% of patients
received at least one transfusion of red blood
cells.  Most transfusions were given in the first
week, and thereafter at a rate of 1–2 units/week.
Mean ± SD time to first transfusion was 2.3 ± 3.7
days (median 1 day).  Transfusion of red blood
cells was associated with worsened patient
outcomes.  These data were similar to Western
European ICU data collected in 1999, when
hemoglobin at baseline, hemoglobin at the time
of transfusion, and association between mortality
and transfusion were evaluated (Vincent JL,
Baron J-F, Reinhart K, et al. Anemia and blood
transfusion in critically ill patients. JAMA
2002;288:1499–507).  (Class II)
Rudis MI, Jacobi J, Hassan E, Dasta JF.
Managing anemia in the critically ill patient.
Pharmacotherapy 2004;24:229–47.
This literature review focuses on the use of
transfusions for acute management of anemia in
critically ill patients.  The risks and benefits of
red blood cell transfusion and the use of blood
substitutes are reviewed.  Despite measures to
reduce blood wastage, many patients develop
anemia of critical illness, characterized by low
red blood cell production despite normal-to-high
concentrations of erythropoietin, and in some
cases inadequate erythropoietin production for
the degree of anemia.  Exogenous erythropoietin
has raised red blood cell production and
corrected anemia in a variety of patient popu-
lations.  The authors make recommendations for
therapy based on the limited data and expert
opinion available.
Corwin HL, Gettinger A, Pearl RG, et al.
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Efficacy of recombinant human erythropoietin in
critically ill patients. JAMA 2002;288:2827–35.
This randomized controlled trial compared
erythropoietin 40,000 U/week with placebo in a
selected medical-surgical ICU population.
Transfusion independence was the primary end
point.  The erythropoietin-treated patients were
less likely than placebo patients to receive a red
blood cell transfusion during the 28-day study,
but their hemoglobin increase was greater than
that of placebo patients.  No significant adverse
effects were reported.  The regimen and end
points were different from those used in an
earlier pilot study (Corwin HL, Gettinger A,
Rodriguez RM, et al. Efficacy of recombinant
human erythropoietin in the critically ill patient.
Crit Care Med 1999;27:2346–50).  This trial,
performed before another study (Hébert PC,
Wells G, Blajchman MA, et al. A multicenter,
randomized, controlled clinical trial of trans-
fusion requirements in critical care. N Engl J Med
1999;340:409–17), compared restrictive versus
liberal transfusion, resulted in a transfusion
trigger higher than currently advocated.  (Class I)
Taylor RW, Manganaro L, O’Brien J, et al.
Impact of allogeneic packed red blood cell
transfusion on nosocomial infection rates in the
critically ill patient. Crit Care Med 2002;30:
2249–54.
The authors searched their clinical database for
information regarding nosocomial infection in
1717 patients in their medical-surgical-trauma
ICU for admissions from October 1998–August
2000.  Risk of infection was calculated based on
the entire cohort—patients receiving and not
receiving red blood cell transfusion.  The overall
nosocomial infection rate was 5.94%, and the
rates were significantly different between the
patients who received (15.3%) and did not
receive (2.9%) transfusion (p<0.005).  This
difference persisted after adjusting for severity of
illness with scores from the Mortality Prediction
Model.  In addition, an association was noted
between the number of units administered and
risk of infection.  Transfused patients had longer
ICU and hospital stays (p<0.0005).  The risk of
nosocomial infection, although not proven to be
the direct result of red blood cell transfusion,
may be the result of transfusion-related
immunosuppression.  Similar results have been
documented in other populations, such as
trauma patients (Claridge JA, Sawyer RG,
Schulman AM, et al. Blood transfusions correlate
with infections in trauma patients in a dose-
dependent manner. Am Surg 2002;68:566–72).
(Class II)
Goodnough LT, Brecher ME, Kanter MH,
AuBuchon JP. Transfusion medicine. N Engl J
Med 1999;340:438–47.
This article, the first of a two-part series,
extensively reviews the risks of blood trans-
fusion, such as human immunodeficiency virus,
hepatitis B and C, and other hepatitis viruses.
Other risks, such as hemolytic reactions, red cell
bacterial contamination, transfusion-related lung
injury, and immunomodulation are also reviewed.
The indications for transfusion reflect the
thinking at the time, although these have been
altered by subsequent reports as described below.
Hébert PC, Wells G, Blajchman MA, et al. A
multicenter, randomized, controlled clinical trial
of transfusion requirements in critical care. N
Engl J Med 1999;340:409–17.
These investigators randomized patients to
either a liberal transfusion strategy designed to
maintain a hemoglobin level of 10–12 g/dl or a
restrictive strategy designed to maintain a
hemoglobin level of 7–9 g/dl.  More red blood
cell transfusions were given to the liberal group,
and although the primary outcome of all-cause
mortality was not different between the groups,
the in-hospital mortality and multiple-organ
dysfunction score were significantly higher in the
liberal group.  These data indicate that a
transfusion threshold as low as 7 g/dl was at least
as effective and possibly superior to a more
liberal transfusion strategy. A trend toward a
lower survival was noted in a subset of patients
with cardiovascular disease from the restrictive
transfusion group.  This led the authors to
suggest that patients with unstable coronary
ischemic syndromes may not benefit from a
restrictive transfusion strategy (Hébert PC, Yetisir
E, Martin C, et al. Is a low transfusion threshold
safe in critically ill patients with cardiovascular
disease? Crit Care Med 2001;29:227–34).  (Class I)
Infection
Bacterial
Centers for Disease Control and Prevention and
the Healthcare Infection Control Practices
Advisory Committee. Guidelines for preventing
health care–associated pneumonia, 2003
guidelines for the prevention of nosocomial
pneumonia. MMWR Morb Mortal Wkly Rep
2004;53(RR-3):1–36.
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This report updates, expands, and replaces the
previously published Guidelines for Prevention
of Nosocomial Pneumonia.  The new guidelines
are designed to reduce the frequency of pneu-
monia and severe, acute lower respiratory tract
infections in acute-care hospitals, other health
care settings (e.g., ambulatory and long-term care
institutions) and other facilities where health
care is provided.  The changes in the recommen-
dations to prevent bacterial pneumonia—
especially ventilator-associated pneumonia—are
directed at endotracheal intubation, water and
environmental purification to avoid Legionella
contamination, administration of palivizumab to
prevent respiratory syncytial virus infection, use
of newer antiviral agents for treatment of
influenza, and identification of pertussis and
lower respiratory tract infections caused by
adenovirus and human parainfluenza viruses.
Chastre J, Wolff M, Fagon J-Y, et al. Comparison
of 8 vs 15 days of antibiotic therapy for
ventilator-associated pneumonia in adults. JAMA
2003;290:2588–98.
A prospective, randomized, double-blind,
clinical trial in 401 patients with ventilator-
associated pneumonia conducted in 51 French
ICUs found no difference in mortality or
recurrent infection in patients treated with
antibiotics for 8 days compared with those
treated for 15 days.  No differences were noted in
resolution of fever, leukocyte count, the ratio of
partial pressure of arterial oxygen to fraction of
inspired oxygen, organ dysfunction, or radiologic
scores between the two treatment groups.  In a
secondary analysis, there were more patients with
nonfermenting gram-negative bacilli infections
treated with 8 days of antibiotics who had
pulmonary infection recurrence.  These data
demonstrated that for intensive care patients with
ventilator-associated pneumonia, there is no
clinical advantage in prolonging antimicrobial
therapy to 15 days compared with 8 days.  (Class I)
Chamot E, El Amari EB, Rohner P, Van Delden
C. Effectiveness of combination antimicrobial
therapy for Pseudomonas aeruginosa bacteremia.
Antimicrob Agents Chemother 2003;47:2756–64.
This is a retrospective analysis of the empiric
treatment of P. aeruginosa bacteremia in 115
episodes over 10 years, from 1988–1998.  The
work is unique in that 30-day mortality was an
end point.  Empiric therapy with combination
antibiotics was associated with a better 30-day
survival rate than empiric monotherapy. No
difference was found in 30-day survival with
monotherapy versus combination therapy if a
definitive treatment was used after receipt of the
culture and sensitivity report.  These data
support the long-held principle that P. aeruginosa
bacteremia is better treated with a combination of
antipseudomonal antibiotics than with mono-
therapy, at least until culture and susceptibility
data have been received.  (Class III)
Cosgrove SE, Sakoulas G, Perencevich E,
Schwaber MJ, Karchmer AQ, Carmeli Y.
Comparison of mortality associated with
methicillin-resistant and methicillin-susceptible
Staphylococcus aureus bacteremia: a meta-
analysis. Clin Infect Dis 2003;36:53–9.
This meta-analysis reviewed mortality
associated with both methicillin-susceptible S.
aureus (MSSA) and methicillin-resistant S. aureus
(MRSA) bacteremia in 31 studies that included
3963 patients; 65.7% had MSSA, 34.3% MRSA.
No significant difference in mortality was found
in 24 studies; higher mortality associated with
MRSA bacteremia was found in seven studies.
When all data were combined, a significant
increase in mortality associated with MRSA
bacteremia was observed.  This increased rate
was also observed in a subgroup analysis in
which adjustment was made for confounding
variables.
Wunderink RG, Rello J, Cammarata SK, Croos-
Dabrera V, Kollef MH. Linezolid vs vancomycin:
analysis of two double-blind studies of patients
with methicillin-resistant Staphylococcus aureus
nosocomial pneumonia. Chest 2003;124:1789–97.
This is a post hoc analysis of two randomized,
double-blind, multicenter studies of linezolid
versus vancomycin for gram-positive nosocomial
pneumonia.  Data on 1019 patients were
combined; 339 patients had documented S.
aureus pneumonia, and 160 had documented
MRSA pneumonia.  Clinical cure rates for MRSA
pneumonia were 50% for linezolid-treated
patients and 35.5% for vancomycin-treated
patients (p<0.01).  The 28-day survival rate for
patients with MRSA pneumonia was 80% with
linezolid versus 63.5% with vancomycin
(p=0.03).  After adjusting for baseline variables,
the difference favoring linezolid remained
significant.  Although this article is a retro-
spective analysis of combined data, it is the first
to demonstrate a survival advantage for one
appropriate antibiotic regimen over another in
patients treated for MRSA pneumonia.  (Class III)
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Neuhauser MM, Weinstein RA, Rydman R,
Danziger LH, Karam G, Quinn JP. Antibiotic
resistance among gram-negative bacilli in U.S.
intensive care units. JAMA 2003;289:885–8.
Antibiotic susceptibility results for 35,790
nonduplicate gram-negative aerobic bacilli
recovered from patients from 1994–2000
representing 43 states and the District of
Columbia were reported.  These results were
compared with those from a similar analysis of
data for 1990–1993.  The activity of most
antimicrobial agents decreased 6% or less over
the study period.  Ciprofloxacin activity
decreased from 89% in 1990–1993 to 86% in
1994 to 76% in 2000.  The decrease in activity of
ciprofloxacin was associated significantly with
the increased national use of fluoroquinolone
therapy during the study period.  Cross-
resistance to other broad-spectrum antibiotics—
such as gentamicin, ceftazidime, imipenem, and
amikacin—was observed in ciprofloxacin-
resistant isolates.
de Gans J, van de Beek D. Dexamethasone in
adults with bacterial meningitis. N Engl J Med
2002;347:1549–56.
This prospective, randomized, double-blind,
multicenter trial involved 301 adult patients with
bacterial meningitis.  Results demonstrated that
dexamethasone 10 mg administered just before
or along with the first dose of antibiotic
(intravenous amoxicillin) and then continued
every 6 hours for 4 days was associated with a
reduced risk of unfavorable outcome as indicated
by the Glasgow Outcome Scale.  Dexamethasone
significantly affected unfavorable outcome in
patients with pneumococcal meningitis but not
meningitis due to Neisseria meningitides. The
proportion of patients who died was significantly
smaller in the dexamethasone group.  Dexa-
methasone did not have a beneficial effect on
neurologic sequelae, including hearing loss.
Although management of meningitis differs
throughout the world, these results support early
treatment with dexamethasone in adults with
bacterial meningitis.  The direct applicability of
these data in countries where vancomycin is the
first-line therapy remains to be determined.
(Class I)
Rello J, Paiva JA, Baraibar J, et al. International
conference for the development of consensus on
the diagnosis and treatment of ventilator-
associated pneumonia. Chest 2001;120:955–70.
This article presents consensus guidelines for
diagnosis and treatment of ventilator-associated
pneumonia.  Twelve European intensivists were
posed 21 questions regarding ventilator-
associated pneumonia.  Answers were inde-
pendently provided, and then were reported to
and discussed among all participants.  The
guidelines cover several important topics,
including initial empiric antibiotic therapy,
monotherapy versus combination antibiotic
therapy, combination therapy for P. aeruginosa
infection, consideration of MRSA, duration of
antibiotic therapy, and deescalation of antibiotic
therapy for the management of ventilator-
associated pneumonia.  Evidence for the
recommendations is provided.
Raymond DP, Pellitier SJ, Crabtree TD, et al.
Impact of rotating empiric antibiotic schedule on
infectious mortality in an intensive care unit. Crit
Care Med 2001;29:1101–8.
The authors present results from a prospective
2-year trial of protocol-driven antibiotic rotation
in a surgical ICU.  In year 1, current practice was
observed; in year 2, quarterly antibiotic rotation
was adopted.  Patients were stratified for rotation
based on diagnosis of either pneumonia, or
peritonitis or sepsis.  A significant reduction in
both gram-positive and gram-negative bacterial
resistance occurred.  A significant reduction in
mortality associated with infection was identified
during the rotation period.  Length of ICU stay
was not affected.  (Class III)
Kollef MH, Sherman G, Ward S, Fraser VJ.
Inadequate antimicrobial treatment of infections:
a risk factor for hospital mortality among
critically ill patients. Chest 1999;115:462–74.
This article demonstrates that critically ill
patients who receive initial antimicrobial therapy
for an infection that does not have activity
against the causative pathogen(s) are signifi-
cantly more likely to die.  Using logistic regres-
sion analysis, the investigators found that
inadequate antimicrobial treatment of infection
was the most important independent predictor of
mortality among the 2000-patient cohort.  The
data also show that up to 45.2% of intensive care
patients with infection receive inadequate
antimicrobial therapy.  (Class II)
Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA,
Muder RR. Antibiotic therapy for Pseudomonas
aeruginosa bacteremia: outcome correlations in a
prospective study of 200 patients. Am J Med
1989;87:540–6.
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Pseudomonas aeruginosa bacteremia is
associated with a high mortality rate.  The aim of
this prospective, observational report, which
involved 200 patients, was to determine whether
in vitro microbiology data translate into
improved outcomes.  Factors associated with
increased mortality were a respiratory portal of
entry, neutropenia, and use of monotherapy.
Combination therapy, compared with mono-
therapy, demonstrated improved survival in
patients with P. aeruginosa bacteremia (p<0.02).
In vitro synergy testing data did not correlate
with improved outcomes.  (Class III)
Fungal
Pappas PG, Rex JH, Sobel JD, et al. Guidelines
for the treatment of candidiasis. Clin Infect Dis
2004;38:161–89.
These guidelines are extensive and detailed
evaluations of the treatment of Candida
infections.  The guidelines followed the U.S.
Public Health Service grading system for rating
recommendations in clinical guidelines.  A
detailed description of susceptibility testing
methods for all antifungal agents and their
interpretations is provided.  Recommendations
include updated dosing guidelines for ampho-
tericin B, amphotericin lipid-based formulations,
and fluconazole.  They also incorporate the use
of voriconazole and caspofungin in the
management of Candida infections.  Specific
recommendations regarding fungal prophylaxis
are provided.
Mora-Duarte J, Betts R, Rotstein C, et al.
Comparison of caspofungin and amphotericin B
for invasive candidiasis. N Engl J Med
2002;347:2020–9.
In this randomized, double-blind, multicenter
study of 239 patients with systemic or invasive
candidiasis, caspofungin produced 73.4%
success, compared with 61.7% for amphotericin
B, in an intent-to-treat analysis.  In a predefined
analysis of patients who met prespecified criteria
for evaluation, 80.7% of caspofungin-treated
patients and 64.0% of amphotericin-treated
patients had successful outcomes (p=0.03).
Caspofungin showed consistently superior
success among stratified subgroups.  Drug-related
adverse effects were significantly higher in the
amphotericin B group.  Failure due to toxic
effects requiring change in therapy occurred
significantly more frequently in the amphotericin
group (16.5%) compared with the caspofungin
group (2.8%; p=0.03).  These data suggest that
caspofungin is an effective yet less toxic
alternative to amphotericin B for invasive
candidiasis.  (Class I)
Rex JH, Bennett JE, Sugar AM, et al. A random-
ized trial comparing fluconazole with ampho-
tericin B for the treatment of candidemia in
patients without neutropenia. N Engl J Med
1994;331:1325–30.
This multicenter, randomized, open-label trial
involved 237 nonneutropenic patients with
candidemia.  Results demonstrated that fluconazole
was equivalent to amphotericin B in overall
clinical success and survival.  Amphotericin B
caused significantly greater elevations in serum
blood urea nitrogen and creatinine levels, and
more hypokalemia, than fluconazole.  The mean
± SD doses used in this study (amphotericin B
0.5 ± 0.01 mg/kg/day, total dose 570 ± 40 mg;
fluconazole 5.3 ± 0.2 mg/kg/day) are somewhat
lower than recommended dosages.  These data
suggested that fluconazole could be considered
for the management of candidemia, which was
previously thought treatable only with ampho-
tericin B.  (Class I)
Sepsis
Dellinger RP, Carlet JM, Masur H, et al. Surviving
sepsis campaign guidelines for management of
severe sepsis and septic shock. Crit Care Med
2004;32:858–72.
These comprehensive guidelines were prepared
by critical care and infectious disease experts
from 11 international organizations.  Recommen-
dations were graded based on a modified Delphi
methodology.  The guidelines cover initial
resuscitation, diagnosis, antibiotic therapy, source
control, fluid therapy, vasopressors, inotropic
therapy, steroids, drotrecogin alfa (activated),
blood product administration, mechanical
ventilation, glucose control, renal replacement
therapy, bicarbonate therapy, deep vein thrombosis
prophylaxis, stress ulcer prophylaxis, consider-
ations for limitations of support, considerations
for pediatric patients, and sedation, analgesia,
and neuromuscular blockade.  This article
represents the culmination of years of research in
sepsis, septic shock, and critical illness.
Annane D, Sebille V, Bollaert P-E, et al. Effect of
treatment with low doses of hydrocortisone and
fludrocortisone on mortality in patients with
septic shock. JAMA 2002;288:862–71.
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This randomized, double-blind, placebo-
controlled, parallel-group, multicenter trial
involved 300 adults with septic shock.  The
investigators evaluated the effects of treatment
with intravenous hydrocortisone 50 mg every 6
hours and enteral fludrocortisone 50 µg once/day
for 7 days on 28-day mortality.  Patients were
stratified based on the results of a short
corticotropin test.  For nonresponders, mortality
was 63% in the placebo group and 53% in the
treatment group (p=0.04).  For responders, as
well as for all patients regardless of corticotropin
test results, there was no significant effect of
corticosteroids on survival.  For nonresponders,
the time to withdrawal of vasopressor support
was 3 days shorter with corticosteroid therapy
than placebo (p=0.001).  No differences in
adverse events were noted between treatment
groups.  These data support corticotropin testing
in patients with septic shock and the adminis-
tration of replacement corticosteroids in patients
with adrenal insufficiency.  (Class I)
Rivers E, Nguyen B, Havstad S, et al. Early goal-
directed therapy in the treatment of severe sepsis
and septic shock. N Engl J Med 2001;345:1368–77.
This prospective, randomized trial involved
263 patients with severe sepsis or septic shock in
an emergency department.  Results showed a
significant 16% absolute improvement in in-
hospital survival for patients receiving 6 hours of
early goal-directed therapy compared with
standard therapy before admission to the ICU.
Early goal-directed therapy consisted of
achieving a central venous pressure of 8–12 mm
Hg or greater, mean arterial pressure of 65–90
mm Hg, and central venous oxygen saturation of
70% or greater.  A protocol for achieving these
goals was used.  Urine output of 0.5 ml/kg/hour
or greater was also a goal, but there was no
specific therapy in the protocol directed toward
urine output.  Goals were achieved in 99.2% of
the early therapy group, compared with 86.1% of
the standard therapy group.  The authors
suggested that goal-directed therapy provided at
the earliest stages of severe sepsis and septic
shock has significant short- and long-term
benefits.  These results may affect the quality and
timing of resuscitation before enrollment in
future trials of sepsis and septic shock.  (Class I)
Bernard GR, Vincent J-L, Laterre P-F, et al.
Efficacy and safety of recombinant human
activated protein C for severe sepsis. N Engl J
Med 2001;344:699–709.
This randomized, double-blind, placebo-
controlled, multicenter trial involved 1690
patients with severe sepsis.  The authors found
that drotrecogin alfa (activated), which is
recombinant human activated protein C, infused
at 24 µg/kg/hour for 96 hours reduced all-cause
28-day mortality from 30.8% to 24.7% (p<0.005).
Reduced relative risk of death was 19.4%.  For
patients at high risk of death, as predefined by
Acute Physiology and Chronic Health Evaluation
II score, drotrecogin alfa (activated) produced an
absolute reduction in mortality of 13%, from 44%
to 31%.  The frequency of severe bleeding was
higher in the treatment than placebo group (3.5%
vs 2.0%, p=0.06).  Drotrecogin alfa (activated)
was approved by the Food and Drug Adminis-
tration for treatment of severe sepsis on the basis
of this trial.  (Class I)
Neurosurgery and Neurology
Spinal Cord Injury
American Association of Neurological Surgeons
and Congress of Neurological Surgeons Joint
Section on Disorders of the Spine and Peripheral
Nerves. Blood pressure management after acute
spinal cord injury: guidelines for the manage-
ment of acute cervical spine and spinal cord
injuries. Chapter 8. Neurosurgery 2002;50(3
suppl):S58–62.
The authors state evidence is insufficient to
support treatment standards or guidelines for
blood pressure management for patients with
acute spinal cord injury.  They do, however,
recommend avoiding hypotension (systolic blood
pressure < 90 mm Hg) and maintaining mean
arterial pressure at 85–90 mm Hg for 7 days after
injury to improve spinal cord perfusion.
American Association of Neurological Surgeons
and Congress of Neurological Surgeons Joint
Section on Disorders of the Spine and
Peripheral Nerves. Pharmacological therapy after
acute cervical spinal cord injury: guidelines for
the management of acute cervical spine and
spinal cord injuries. Chapter 9. Neurosurgery
2002;50(3 suppl):S63–72.
This is one of the most controversial chapters
in the guidelines, and the authors recommend
that readers review the data and comments to
formulate their own opinions regarding treat-
ment options.  They state that there is insufficient
evidence for treatment standards or guidelines for
using corticosteroid therapy.  The group recom-
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mends that methylprednisolone administered for
24–48 hours can be considered a treatment
option for patients with acute spinal cord injury;
however, the authors first acknowledge that the
evidence suggesting harmful side effects is more
consistent than evidence supporting clinical
benefit.
American Association of Neurological Surgeons
and Congress of Neurological Surgeons Joint
Section on Disorders of the Spine and
Peripheral Nerves. Deep venous thrombosis and
thromboembolism in patients with cervical spinal
cord injuries: guidelines for the management of
acute cervical spine and spinal cord injuries.
Chapter 10. Neurosurgery 2002;50(3 suppl):
S73–80.
In this chapter, prophylaxis of deep vein
thrombosis is recommended as a standard of care
for patients with acute spinal cord injury.  The
authors support the use of low-molecular-weight
heparins, rotating beds, adjusted-dose heparin, or
a combination of these modalities, as well as low-
dose heparin in combination with pneumatic
compression stockings or electrical stimulation
as treatment strategies for prophylaxis.  The
guidelines state that low-dose heparin therapy
alone and oral anticoagulation alone are not
recommended.  Other suggestions include the
administration of various diagnostic tests, 3
months of prophylactic treatment, and vena cava
filters for patients not responding to anti-
coagulation or who have contraindications to
anticoagulation and/or mechanical devices.
Hurlbert RJ. Methylprednisolone for the acute
cord injury: an inappropriate standard of care. J
Neurosurg Spine 2000:93:1–7.
This article provides a critical evaluation of the
results and conclusions of the National Acute
Spinal Cord Injury Studies (NASCIS) II and III to
determine the influence they should have on
practice standards for patients with acute spinal
cord injury.  The author converted the published
data from these trials into the original raw data to
further evaluate the effects on outcome.  He
concluded that although these studies were well
designed and well conducted, evidence to
support the use of methylprednisolone therapy
for patients with acute spinal cord injury is weak
and clinically irrelevant.  He suggested that
administration of methylprednisolone should be
considered experimental, and the 48-hour
treatment regimen should not be recommended.
Bracken MB, Shepard MJ, Holford TR, et al.
Administration of methylprednisolone for 24 or
48 hours or tirilazad mesylate for 48 hours in the
treatment of acute spinal cord injury: results of
the third national acute spinal cord injury
randomized controlled study. JAMA
1997;277:1597–604.
The NASCIS III was a double-blind,
randomized, controlled trial involving 499
patients with acute spinal cord injury.  At 6-week
and 6-month follow-up, a significant neurologic
recovery persisted with the 48-hour
methylprednisolone regimen that had been
started within 3–8 hours after injury compared
with the 24-hour regimen (neurologic change
scores at 6 weeks, 7.6 vs 12.5, p=0.04; at 6
months, 11.2 vs 17.6, p=0.01).  No difference in
recovery was found when treatment was started
within 3 hours of injury.  In a third study group,
tirilazad demonstrated efficacy similar to that of
the 24-hour methylprednisolone regimen and
was well tolerated.  The authors concluded that
methylprednisolone therapy should be continued
for 24 hours if started within 3 hours of injury,
but continued for 48 hours if started 3–8 hours
after injury. (Class I)
Bracken MB, Shepard MJ, Collins WF, et al. A
randomized, controlled trial of methylprednisolone
or naloxone in the treatment of acute spinal-cord
injury: results of the second national acute spinal
cord injury study. N Engl J Med 1990;322:1405–11.
In the NASCIS I trial, methylprednisolone in
dosages up to 1000 mg/day did not improve
neurologic recovery (sensory or motor function)
in 330 patients with acute spinal cord injury.
This article describes NASCIS II, a double-blind,
placebo-controlled trial involving 487 patients
treated within 8 hours of injury.  Treatment
consisted of a high-dose methylprednisolone
intravenous bolus of 30 mg/kg followed by
continuous infusion of 5.4 mg/kg/hour for 23
hours.  Significant motor function and sensation
were maintained at 6 weeks and 6 months with
methylprednisolone compared with placebo or a
naloxone bolus of 5.4 mg/kg followed by infusion
of 4 mg/kg/hour for 23 hours.  Complication
rates were similar among the three groups.
(Class I)
Head Injury
CRASH Trial Collaborators. Effect of intravenous
corticosteroids on death within 14 days of 10008
600
KEY ARTICLES AND GUIDELINES ON ICU PHARMACOLOGY—2004  Erstad et al
adults with clinically significant head injury
(MRC CRASH trial): randomized placebo-
controlled trial. Lancet 2004;364:1321–8.
The Medical Research Council’s Corticosteroid
Randomization After Significant Head Injury
(MRC CRASH) trial was a multicenter, randomized,
placebo-controlled trial involving 10,008 adults
with severe head injury.  The goal was to
determine the effect of early administration of
methylprednisolone on risk of death at 2 weeks
or disability at 6 months.  Patients were randomized
to receive intravenous methylprednisolone 2 g
followed by 0.4 g/hour for 48 hours, or placebo,
within 8 hours of injury.  The study was stopped
prematurely because an interim analysis showed
a significant increase in relative risk of all-cause
death in the methylprednisolone-treated group
(RR 1.18, 95% CI 1.09–1.27, p=0.0001).  The
relative increase in mortality in the methyl-
prednisolone group did not differ by the severity
or time of injury.  The exact mechanism for the
increased mortality is unknown.  This is the first
study that clearly refutes the mortality benefit of
corticosteroids in the treatment of patients with
severe head injury.  (Class I)
Bullock RM, Chesnut RM, Clifton GL, et al. Use
of mannitol. J Neurotrauma 2000;17:521–5.
Mannitol is an osmotic diuretic used to control
raised intracranial pressure in patients with
severe head injury.  This is a task force–based
guideline for treatment of traumatic intracranial
hypertension with mannitol.  The authors
suggest that a bolus dose may be more effective
than a continuous infusion.  In addition, they
advocate keeping serum osmolality below 320
mOsm/kg and avoiding hypovolemia to minimize
the risk of acute tubular necrosis.
Bullock RM, Chesnut RM, Clifton GL, et al. Use
of barbiturates in the control of intracranial
hypertension. J Neurotrauma 2000;17:527–30.
In patients with severe head injury, uncontrolled
intracranial hypertension is associated with a
high risk of mortality (84–100%).  This article
consists of guidelines for the use of barbiturates
in treating such patients.  In hemodynamically
stable patients, high-dose barbiturates may be
administered to lower intracranial pressure
refractory to conventional medical or surgical
treatment.  Efficacy has not been proven for pro-
phylactic lowering of intracranial pressure.
These guidelines were based on a task force review.
Bullock RM, Chesnut RM, Clifton GL, et al.
Role of steroids. J Neurotrauma 2000;17:531–5.
Steroids have been investigated as a means to
control raised intracranial pressure in patients
with head trauma.  This task force review did not
support steroid administration because most of
the available evidence does not suggest improved
outcomes or lowered intracranial pressure.
Bullock RM, Chesnut RM, Clifton GL, et al.
Role of antiseizure prophylaxis following head
injury. J Neurotrauma 2000;17:549–53.
These guidelines were based on a task force
review of the literature on anticonvulsants for
posttraumatic seizure prophylaxis.  The authors
concluded that phenytoin and carbamazepine
decreased the risk of early posttraumatic seizure
(defined as seizure onset within 7 days of injury).
Improved survival benefit was not proven.  The
authors suggested valproic acid as an alternative
agent, although it has been associated with a
slightly higher mortality.
Haltiner AM, Newell DW, Temkin NR, Dikmen
SS, Winn HR. Side effects and mortality
associated with the use of phenytoin for early
posttraumatic seizure prophylaxis. J Neurosurg
1999;91:588–92.
According to a secondary analysis of a
prospective, randomized, double-blind, placebo-
controlled trial, improved survival was not
associated with the reduction of early post-
traumatic seizures (within 7 days of injury) in
404 patients receiving phenytoin.  Hyper-
sensitivity reactions to phenytoin, primarily an
idiosyncratic maculopapular rash, increased from
0.6% during week 1 to 2.5% during week 2.
Overall, short-term phenytoin therapy was well
tolerated.  The authors suggest that mortality in
patients who developed posttraumatic seizures
might be linked to increased severity of the
original traumatic brain injury. (Class II)
Temkin NR, Dikmen SS, Anderson GD, et al.
Valproate therapy for prevention of posttraumatic
seizures: a randomized trial. J Neurosurg
1999;91:593–600.
Seizures are common in patients with recent
traumatic brain injury. This randomized,
controlled trial compared a 7-day course of
phenytoin (132 patients) with a 1-month (120
patients) and 6-month (127 patients) course of
valproate for prevention of seizures associated
with head trauma.  Differences in the frequencies
of seizures, mortality, and adverse effects were
not statistically significant between groups.  A
trend toward higher mortality was found in the
valproate group; however, none of the deaths
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were attributable to the most common adverse
effects reported—liver dysfunction and
thrombocytopenia.  The authors concluded that
valproate should not be routinely used for
prophylaxis of posttraumatic seizures.  (Class I)
Temkin NR, Dikmen SS, Wilensky AJ, Keihm J,
Chabal S, Winn HR. A randomized, double-blind
study of phenytoin for the prevention of post-
traumatic seizures. N Engl J Med 1990;323:
497–502.
This randomized, double-blind, placebo-
controlled study is the landmark article
supporting short-course phenytoin therapy for
seizure prophylaxis in patients with severe head
injury.  Phenytoin (20-mg/kg load) or placebo
was administered within 24 hours of injury, and
maintenance doses were continued for 12
months.  Phenytoin doses were adjusted to
maintain free phenytoin levels within a target
range of 0.75–1.5 mg/L.  Patients were followed
for 24 months.  One week after injury, the seizure
rate was 3.6% and 14.2% in the phenytoin and
placebo groups, respectively (p<0.001).  The
differences in the frequency of late-onset seizures
(day 8–year 2) between groups was not
statistically significant (p>0.2).  The authors
concluded that phenytoin is effective only for
prevention of early-onset (< 7 days) seizures after
severe head injury.  (Class I)
Hemorrhagic Stroke
Fewel ME, Park P. The emerging role of
recombinant-activated factor VII in neurocritical
care. Neurocrit Care 2004;1:19–30.
Factor VII is beginning to play a role in the
area of neurocritical care.  A review of the
pharmacology, pharmacokinetics, and treatment
strategies in the critically ill neurosurgical patient
population is discussed.  The authors also review
recently published case studies.  This article
provides a nice overview of factor VII treatment
options in neurocritical care.
Sen J, Belli A, Albon H, Morgan L, Ptezold A,
Kitchen N. Triple-H therapy in the management
of aneurysmal subarachnoid haemorrhage.
Lancet Neurol 2003;2:614–21.
Vasospasm, a major complication after
subarachnoid hemorrhage, is associated with
high morbidity and mortality.  Hypervolemia,
hypertension, and hemodilution (triple-H)
therapy is accepted as a standard of care;
however, no randomized, controlled trials have
been conducted to prove efficacy in the treatment
of vasospasm.  The authors review the literature
and discuss the rationale for triple-H therapy.
Broderick JP, Adams HP, Barsan W, et al.
Guidelines for the management of spontaneous
intracerebral hemorrhage: a statement for
healthcare professionals from a special writing
group of the stroke council of the American
Heart Association. Stroke 1999;30:905–15.
A task force was formed to develop practice
guidelines for the management of intracerebral
hemorrhage.  These guidelines provide recom-
mendations for diagnosis, acute treatment,
medical management, surgical treatment, and
prevention of intracerebral hemorrhage.  Algor-
ithms for the management of blood pressure and
intracranial pressure, parameters for fluid
management, and recommendations for seizure
prophylaxis and temperature regulation are
provided.
Ischemic Stroke
Adams HP, Adams RJ, Brott T, et al. Guidelines
for the early management of patients with
ischemic stroke: a statement from the stroke
council of the American Stroke Association.
Stroke 2003;34:1056–83.
These guidelines, which update the original
1994 guidelines, are intended to guide clinicians
in the diagnosis and management of patients
during the first 24–48 hours after ischemic
stroke.  Recommendations are provided for
diagnostic testing and examination, general
supportive care and treatment of complications,
use of thrombolysis, role of anticoagulation,
surgical interventions, and management of
neurologic complications.  Each recommendation
is graded based on the level of supporting
evidence.
Albers GW, Bates VE, Clark WM, Bell R, Verro
P, Hamilton SA. Intravenous tissue-type
plasminogen activator for treatment of acute
stroke: the standard treatment with alteplase to
reverse stroke (STARS) study. JAMA 2000;283:
1145–50.
The aim of this trial was to report the clinical
outcomes and adverse effects of tissue-type
plasminogen activator when used in practice.
The 30-day clinical outcomes of intravenous
tissue–type plasminogen activator 0.9 mg/kg,
maximum 90 mg, were investigated in 389
consecutive patients with acute ischemic stroke.
The 30-day mortality was 13%; in addition, 35%
of patients had a very favorable outcome and
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43% were functionally independent (modified
Rankin scores of ≤ 1 and ≤ 2, respectively).
Safety data from this observational study were
consistent with the low frequency of
symptomatic intracranial hemorrhage found in
the National Institute of Neurological Disorders
and Stroke trial.  Caution should still be
exercised for patients with major early infarction.
(Class II)
Clark WM, Wissman S, Albers GW, Jhamandas
JH, Madden KP, Hamilton S. Recombinant
tissue–type plasminogen activator (alteplase) for
ischemic stroke 3 to 5 hours after symptom
onset: the ATLANTIS study: a randomized
controlled trial. JAMA 1999;282:2019–26.
Recombinant tissue–type plasminogen activator
originally was studied when administered within
3 hours of symptom onset in patients with acute
ischemic stoke.  However, only a few patients
received the drug within this time frame.  In this
randomized, placebo-controlled trial, alteplase
was initiated in 3–5 hours after symptom onset.
Outcomes were neurologic recovery at 90 days,
functional outcome measures at 30 and 90 days,
and serious adverse events.  Neurologic recovery,
functional recovery, and mortality were similar in
both groups.  Asymptomatic, symptomatic, and
fatal intracranial hemorrhages were significantly
higher in the alteplase group (p<0.05).  The
authors concluded that there was no benefit to
administering alteplase 3–5 hours after symptom
onset.  (Class I)
Hacke W, Kaste M, Fieschi C, et al. Randomised
double-blind placebo-controlled trial of
thrombolytic therapy with intravenous alteplase
in acute ischaemic stroke (ECASS II). Lancet
1998;352:1245–51.
The primary objective of this multicenter trial
was to determine whether alteplase 0.9 mg/kg
given within 6 hours of symptom onset would
improve overall function in 800 patients with
acute ischemic stroke.  Efficacy of alteplase was
independent of administration time (no
difference when given < 3 or 3–6 hrs after
stroke).  No significant difference in efficacy or
mortality was observed between alteplase and
placebo at the 30- and 90-day end points.  As
seen in the first European Cooperative Acute
Stroke Study (ECASS I) and the National
Institute of Neurological Disorders and Stroke
(NINDS) trial, symptomatic intracranial
hemorrhage was higher in the alteplase group
(8.8%) than in the placebo group (3.4%).  (Class I)
NINDS t-PA Stroke Study Group. Intracerebral
hemorrhage after intravenous t-PA therapy for
ischemic stroke. Stroke 1997;28:2109–18.
Administration of tissue plasminogen activator
(t-PA) has been associated with increased risk of
intracranial hemorrhage when used to treat
ischemic stroke.  The authors investigated
whether any variables collected in the NINDS
t-PA stroke trial were associated with intracranial
hemorrhage.  Severity of neurologic deficit (OR
1.8, 95% CI 1.2–2.9) and brain edema and mass
effect by computed tomography (OR 7.8, 95% CI
2.2–27.1) were the only independent variables
associated with intracranial hemorrhage.
Patients with severe neurologic deficits had more
favorable outcomes at 90 days in the treatment
group than in the placebo group (OR 4.3, 95% CI
1.6–11.9).  The authors concluded that these
patients were still candidates for t-PA if the agent
was administered within 3 hours of symptom
onset.  (Class II)
National Institute of Neurological Disorders
and Stroke rt-PA Stroke Study Group. Tissue
plasminogen activator for acute ischemic stroke.
N Engl J Med 1995;333:1581–7.
Previous trials have suggested that early
intervention with thrombolytic therapy improves
clinical outcomes in patients with acute ischemic
stroke, although the therapy is associated with a
risk of symptomatic intracranial hemorrhage.  In
this prospective, randomized, double-blind,
placebo-controlled trial, 624 patients were treated
with recombinant tissue plasminogen activator
(rt-PA) 0.9 mg/kg, maximum 90 mg.  The results
demonstrated significantly decreased neurologic
deficit at 3 and 12 months in patients treated
within 3 hours of stroke onset (OR 1.7, 95% CI
2–2.6).  Symptomatic intracranial hemorrhage
occurred more frequently in the rt-PA group
(6.4%) than in the placebo group (0.6%) during
the first 36 hours (p<0.001).  No difference in
mortality was detected.  (Class I)
Hacke W, Kaste M, Fieschi C, et al. Intravenous
thrombolysis with recombinant tissue plas-
minogen activator for acute hemispheric stroke:
the European cooperative acute stroke study
(ECASS). JAMA 1995;274:1017–25.
Restoration of cerebral blood flow is the goal of
thrombolytic therapy in stroke patients.  This
randomized, controlled trial compared rt-PA with
placebo in 620 patients with acute ischemic
stroke.  The patients presented within 6 hours of
symptom onset and had experienced a stable
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(moderate-to-severe) stroke without signs of
infarction on computed tomography.  No
difference in the primary outcome of functional
scores at 90 days was found with the intent-to-
treat analysis.  The target population analysis
revealed that one of the functional scores
(Rankin score) was in favor of rt-PA (p<0.05).
Mortality was similar between the two groups,
but parenchymal hemorrhages and mortality
occurred significantly more often in the rt-PA
group.  The authors concluded that rt-PA was
effective, and that the risk of bleeding and death
does not outweigh the positive effects of t-PA.
They recommended more stringent criteria for
patient selection to reduce adverse effects.  (Class I)
Seizures
Lowenstein DH. Treatment options for status
epilepticus. Curr Opin Pharmacol 2003;3:6–11.
Progress in technology and diagnostic tools
have enhanced our understanding and appre-
ciation of the complexities of status epilepticus.
This review article addresses the treatment of
status epilepticus, focusing on pharmacology and
providing both clinical and pharmacologic
rationales for therapy.  The author advocates
individualized algorithms based on patient
response to treatment and discusses treatment
options not available at the time of a 1998 review
(Lowenstein DH, Alldredge BK. Current
concepts: status epilepticus. N Engl J Med
1998;338:970–6).  The author concluded that
more aggressive therapies are likely to be
required if patients do not respond to first-line
drugs.  However, large-scale clinical trials to
determine the safety and efficacy of new, more
potent agents are still lacking.
Claasen J, Hirsch LJ, Emerson RG, Mayer SA.
Treatment of refractory status epilepticus with
pentobarbital, propofol, or midazolam: a
systematic review. Epilepsia 2002;43:146–53.
The absence of controlled, prospective studies
comparing available treatment options for
refractory status epilepticus makes it difficult to
compare the relative efficacy and safety of these
options.  This article provides a systematic review
of peer-reviewed publications reporting the
treatment of adults with status epilepticus
refractory to at least two standard anti-
convulsants.  Outcome measures evaluated were
the frequency of short-term treatment failure
(within 1–6 hrs), mortality, and drug titration
goals.  Twenty-eight publications describing 193
patients receiving pentobarbital, propofol, or
midazolam were included in the analysis.  Of the
193 patients, 48% died, with no differences based
on the treatment received.  Although pentobarbital
was usually titrated to electroencephalogram
background suppression, propofol and midazolam
were titrated to the dosage needed to achieve
seizure suppression.  Overall, the limited data
reviewed in this article suggest that treatment
with pentobarbital or titration of any agent to
electroencephalogram background suppression
may be the most effective strategy for managing
refractory status epilepticus.  However, there was
no obvious improvement in mortality.  Prospective,
controlled evaluations of this issue are needed.
Lowenstein DH, Alldredge BK. Current
concepts: status epilepticus. N Engl J Med
1998;338:970–6.
This article provides a concise and clinically
useful review of the clinical presentation,
pathophysiology, initial management, and
pharmacologic treatment of status epilepticus.
The review contains a treatment algorithm that is
widely employed in the management of patients
with status epilepticus.
Treiman DM, Meyers PD, Walton NY, et al. A
comparison of four treatments for generalized
convulsive status epilepticus. N Engl J Med
1998;339:792–8.
In this multicenter, randomized, double-blind
trial, four intravenous regimens were compared
for in-hospital treatment of generalized
convulsive status epilepticus.  A total of 570
patients were randomized to receive diazepam
0.15 mg/kg followed by phenytoin 18 mg/kg,
lorazepam 0.1 mg/kg, phenobarbital 15 mg/kg, or
phenytoin 18 mg/kg.  Treatment success was
defined as the absence of motor and electrical
activity within 20 minutes of drug infusion, with
no evidence of recurrence over the next 40
minutes.  Intent-to-treat analysis revealed no
statistically significant differences among
regimens.  For 384 patients with overt
generalized convulsive seizures, lorazepam was
more effective than phenytoin (p=0.02) but did
not differ from the diazepam-phenytoin and
phenobarbital regimens.  Based on at least
comparable safety and efficacy for the four
regimens, the authors concluded that for patients
with generalized convulsive status epilepticus,
lorazepam should be the initial treatment due to
its ease of administration and improved response
compared with phenytoin.  (Class I)
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Nutrition
Jacobs DG, Jacobs DO, Kudsk KA, et al. Practice
management guidelines for nutritional support of
the trauma patient. J Trauma 2004;57:660–79.
This guideline was developed by a work group
of EAST.  Each of the six guideline subsections
(route, timing, site, macronutrients, monitoring,
and type of nutritional support) is a freestanding,
evidence-based document.  References and
evidence tables associated with the guideline can
be obtained on the EAST Web site (http://www.
east.org).  The guideline contains an algorithm
summarizing the nutritional management of
trauma patients.
Barr J, Hecht M, Flavin KE, et al. Outcomes in
critically ill patients before and after the
implementation of an evidence-based nutritional
management protocol. Chest 2004;125:1446–57.
The primary end point of this before-and-after,
prospective investigation (100 patients in each
phase) was to evaluate the impact of a nutritional
management protocol on the time to initiation of
feeding of patients in two medical-surgical ICUs.
The protocol was evidence based but lacked
high-level evidence for some recommendations.
Enteral versus parenteral nutrition, ability to
reach caloric goals, and length of ICU stay were
evaluated.  Patients in the postimplementation
group were more likely than those in the
preimplementation group to be fed enterally, and
their mean duration of mechanical ventilation
was decreased.  However, the results were
statistically significant (p=0.009 and p=0.03,
respectively) only after adjusting for a variety of
covariates, such as baseline nutritional status and
severity of illness.  The logic behind this adjust-
ment was questioned in an editorial accompanying
the article (Zaloga GP, Bortenschlager L. Anorexia
protocolis. Chest 2004;125:1195–7).  No other
significant differences between groups were
noted, probably because of the comparable
number of patients receiving enteral feeds in the
preprotocol and postprotocol groups (68% and
78%, respectively, p=0.08).  This study is notable
because of its prospective design and
comprehensive approach to the nutritional
management of critically ill patients.  (Class II)
American Society of Parenteral and Enteral
Nutrition Board of Directors and the Clinical
Guidelines Task Force. Guidelines for the use of
parenteral and enteral nutrition in adult and
pediatric patients. J Parenter Enteral Nutr
2002;26(suppl):1SA–96.
Based on an extensive review of the literature,
an interdisciplinary, technical advisory group of
nutrition support specialists updated the 1993
guidelines to assist clinicians in managing
patients in both outpatient and inpatient settings.
Each topic is presented in the same format:
background, evidence, special considerations (if
applicable), and graded recommendations for
specialized nutrition support.
Heyland DK, Novak F, Drover JW, Jain M, Su X,
Suchner U. Should immunonutrition become
routine in critically ill patients? JAMA
2001;286:944–53.
The appropriate indications for the use of
enteral feeding formulas supplemented with
immune-altering nutrients in the ICU are
controversial despite the availability of consensus
guidelines (Kudsk KA, Moore F, Martindale RG,
Cresci G, McClave S, Schloerb PR. Consensus
recommendations from the U.S. summit on
immune-enhancing enteral therapy. J Parenter
Enteral Nutr 2001;25(suppl):S61–2).  This meta-
analysis is important not only because it evaluates
the use of such formulas in critically ill patients,
but also because it raises important questions and
concerns regarding research in this area.
Heyland DK, MacDonald S, Keefe L, Drover JW.
Total parenteral nutrition in the critically ill
patient: a meta-analysis. JAMA 1998;280:2013–19.
This meta-analysis of 26 randomized trials
evaluated morbidity and mortality outcomes in
2211 surgical or critically ill patients receiving
total parenteral nutrition (TPN).  Although TPN
did not improve mortality, a trend toward
decreased complication rates was found in
patients classified as malnourished.
Veterans Affairs Total Parenteral Nutrition
Cooperative Study Group. Perioperative total
parenteral nutrition in surgical patients. N Engl J
Med 1991;325:525–32.
Outcome data for morbidity and mortality in
surgical patients requiring TPN are lacking in the
published literature.  The primary objective of
this prospective, randomized, controlled trial was
to determine whether perioperative TPN
decreased serious complications secondary to
major abdominal or thoracic surgery. A total of
395 patients were randomized—192 to the TPN
group and 203 to the control group.  Rates of
major complications, mortality, and noninfec-
tious complications were not statistically
significant between the two groups.  Patients
receiving TPN had more infectious complications
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than controls (14.1% vs 6.4%, RR 2.20, 95% CI
1.19–4.05).  Severely malnourished patients,
however, experienced an overall benefit from
TPN since a significantly lower rate of infectious
complications was found in this group (RR 0.12,
95% CI 0.02–0.91).  (Class I)
Sedation, Analgesia, Delirium, and
Neuromuscular Blockade
Baumann MH, McAlpin W, Brown K, et al. A
prospective randomized comparison of train-of-
four monitoring and clinical assessment during
continuous ICU cisatracurium paralysis. Chest
2004;126:1267–73.
These authors tested the recommendation from
the guidelines of the Society of Critical Care
Medicine and the American Society of Health-
System Pharmacists for routine use of a
peripheral nerve stimulator with continuous
neuromuscular blockade.  Medical intensive care
patients were randomized to train-of-four every 4
hours versus clinical assessment during
cisatracurium infusions of 50–70 hours.
Cisatracurium was titrated to maintain one or
two of four twitches.  No difference was demon-
strated in time to recovery of neuromuscular
function (four of four twitches) or dosing
requirement for the 30 patients studied.  The
authors suggested that routine use of train-of-
four was not needed during cisatracurium
infusion.  The article and its accompanying
editorial (Sessler CN. Train-of-four to monitor
neuromuscular blockade? Chest 2004;126:
1018–22) correctly suggest that these data cannot
be extrapolated to infusions of aminosteroidal
neuromuscular blockade agents, whereas accu-
mulation of active metabolites may contribute to
prolonged drug effects.  (Class I)
Vasile B, Rasulo F, Candiani A, Latronico N. The
pathophysiology of propofol infusion syndrome:
a simple name for a complex syndrome. Intensive
Care Med 2003;29:1417–25.
The authors developed a hypothesis for the
development of a syndrome characterized by
cardiac failure, rhabdomyolysis, severe metabolic
acidosis, and renal failure after prolonged or
high-dose propofol infusion.  This syndrome
appears to be rare; only 21 pediatric and 14 adult
cases have been reported in the literature.  Most
of the reports involve patients with neurologic
illnesses or acute inflammatory diseases (e.g.,
severe sepsis) as priming factors in combination
with triggering factors, such as concurrent
catecholamine infusions or steroids.  Propofol
doses greater than 5 mg/kg/hour for more than
48 hours were reported in the cases described.
Ely EW, Truman B, Shintani A, et al. Monitoring
sedation status over time in ICU patients:
reliability and validity of the Richmond agitation-
sedation scale (RASS). JAMA 2003;289:2983–91.
The RASS is a modification of the Riker
Sedation-Agitation Scale, expanded to score 10
levels rather than the original seven.  In
particular, the degrees of light sedation are
expanded to differentiate response to voice from
response to physical stimulation.  This prospective
cohort trial evaluated the RASS used in adult
patients in medical and coronary ICUs compared
with the Glasgow Coma Scale and Ramsay scale.
The study serves as an independent validation of
the utility of the RASS.  In 290 paired obser-
vations by nurses, the RASS and Ramsay scale
both demonstrated excellent interrater reliability
as well as criterion, construct, and face validity.
Both were superior to the Glasgow Coma Scale.
The RASS detected changes in sedation status
over consecutive days in patients with varying
levels of consciousness and delirium.  Scores
changed appropriately with dosages of sedatives
and analgesics.  (Class II)
Odhner M, Wegman D, Freeland N, et al.
Assessing pain control in nonverbal critically ill
adults. Dimens Crit Care Nurs 2003;22:260–7.
This is the second observational pain scale to
be published and validated at the site of origin.
The nonverbal pain scale yields a score of 0–2 for
each of the major categories (facial expression,
activity [movement], guarding, vital signs, and
skin appearance), for a potential score of 0–10.
Validation occurred with 100 paired assessments
on all three 8-hour nursing shifts, although most
tests were performed during the day.  The
nonverbal pain scale was compared with a
pediatric scale for face, legs, activity, cry, and
consolability due to the lack of a previous gold
standard for assessment of nonverbal patients.
Interrater reliability for the nonverbal pain scale
was good (a=0.78).  However, no assessment was
performed to ensure that the change on the
nonverbal pain scale was correlated with different
degrees of pain.  (Class II)
Nasraway SA, Jacobi J, Murray MJ, Lumb PA.
Sedation, analgesia, and neuromuscular blockade
of the critically ill adult: revised clinical practice
guidelines for 2002. Crit Care Med 2002;30;
117–18.
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This introductory document accompanies two
corresponding guideline documents (described
below) developed jointly by the American Society
of Health-System Pharmacists and the Society of
Critical Care Medicine.  Levels of evidence and
definitions for the grades of recommendation are
described in this document.  The three articles in
this series have also been published elsewhere
(Am J Health-Syst Pharm 2002;59:147–95).
Jacobi J, Fraser GL, Coursin DB, et al. Clinical
practice guidelines for the sustained use of
sedatives and analgesics in the critically ill adult.
Crit Care Med 2002;30:119–41.
This guideline, second in the series of three
articles, summarizes the extensive literature on
analgesia and sedation of critically ill patients
with emphasis on patient assessment, therapeutic
options, and recommendations for optimal
therapy.  Examples of assessment tools are
provided along with an algorithm approach to
treatment plan development.  Associated topics
include management of delirium and issues
related to nonpharmacologic therapy and sleep.
Murray MJ, Cowen J, DeBlock H, et al. Clinical
practice guidelines for sustained neuromuscular
blockade in the adult critically ill patient. Crit
Care Med 2002;30:142–56.
The third article in this series similarly
summarizes the literature on the use of
neuromuscular blocking agents in critical care
patients.  The authors describe the mechanism of
action and the pharmacology of the individual
agents.  They also describe the appropriate
indications and recommended agents, along with
suggestions for how to monitor for effectiveness
and adverse effects.  The article also reviews the
syndromes and risk factors leading to delayed
muscle recovery after treatment with these
agents.  A template for evaluation of the
pharmacoeconomic impact of individual agents is
provided.
Barr J, Zomorodi K, Bertaccini EJ, et al. A
double-blind, randomized comparison of IV
lorazepam versus midazolam for sedation of ICU
patients via a pharmacologic model. Anesthe-
siology 2001;95:286–98.
In this double-blind clinical trial, 24 mecha-
nically ventilated patients were randomized after
surgery to receive sedation with lorazepam or
midazolam by continuous infusion for 12–72
hours.  Sedation was titrated through infusion
rate changes with a goal of Ramsay scale level
3–4.  Serum concentrations and pharmaco-
dynamic effects were also measured.  The
estimated sedative potency of lorazepam was
twice that of midazolam on a milligram-to-
milligram basis.  The relative amnesic potency of
lorazepam was 4 compared with midazolam.
Lorazepam was associated with longer times to
emergence from 72 hours of sedation with both
deep (31.1 hrs) and light (11.9 hrs) regimens
compared with deep and light regimens of
midazolam (14.9 and 3.9 hrs, respectively).
However, excluding patients with renal or
hepatic insufficiency may have minimized
accumulation of midazolam’s active metabolites
that could alter awakening times.  (Class I)
Garnacho-Montero J, Madrazo-Osuna J, Garcia-
Garmendia JL, et al. Critical illness poly-
neuropathy: risk factors and clinical conse-
quences. A cohort study in septic patients.
Intensive Care Med 2001;27:1288–96.
Intensive care patients can experience
prolonged weakness after a critical illness such as
sepsis.  Myopathy treated with corticosteroids has
been well described, and the potential contribu-
tion of neuromuscular blocking agents was well
documented in the neuromuscular blocking
agent guidelines.  In this article, the authors
studied 73 patients with sepsis and assessed
neuromuscular changes with electrophysiologic
studies on the days 10 and 21 of mechanical
ventilation.  Multivariate logistic regression
analysis of the risk factors for critical-illness
polyneuropathy demonstrated that hyper-
osmolality, parenteral nutrition, neuromuscular
blocking agents, and neurologic failure were
independently associated with critical-illness
polyneuropathy, whereas renal replacement
therapy appeared protective.  Forty six patients
had critical-illness polyneuropathy on the first
assessment, with an additional four diagnosed at
the second evaluation.  As demonstrated by
others, critical-illness polyneuropathy contributed
to a longer duration of mechanical ventilation
and hospital stay. (Class II)
Kress JP, Pohlman AS, O’Connor MF, Hall JB.
Daily interruption of sedative infusions in
critically ill patients undergoing mechanical
ventilation. N Engl J Med 2000;342:1471–7.
In this study, 128 critically ill, mechanically
ventilated patients were randomized to daily
interruption of sedative infusion or routine
sedative titration.  Patients were further ran-
domized to therapy with propofol or midazolam.
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Duration of mechanical ventilation was reduced
from 7.3 to 4.9 days (p=0.004) with daily
sedative interruption.  Length of stay in the ICU
was also significantly reduced.  Additional
information was reported in subsequent
publications (Kress JP, Pohlman AS, Hall JB.
Effects of sedative interruption in critically ill,
mechanically ventilated patients receiving
midazolam or propofol. J Clin Outcomes Manage
2001;8:33–9; and Kress JP, Gelbach B, Lacy M, et
al. The long-term psychological effects of daily
sedative interruption on critically ill patients. Am
J Resp Crit Care Med 2003;168:1457–61).  (Class I)
Toxicology
Mokhlesi B, Leikin JB, Murray P, Corbridge TC.
Adult toxicology in critical care. Part I. General
approach to the intoxicated patient. Chest
2003;123:577–92.
Mokhlesi B, Leikin JB, Murray P, Corbridge TC.
Adult toxicology in critical care. Part II. Specific
poisonings. Chest 2003;123:897–922.
This two-part series provides a comprehensive
review of the evaluation, treatment, and outcome
of common overdoses and intoxications from the
perspective of the critical care practitioner. The
first review focuses on the general management
of the intoxicated patient, including physical
examination and laboratory findings of common
toxidromes, nonspecific supportive therapies,
and detoxification.  The second review discusses
the management of specific intoxicants and
poisons.
Zimmerman JL. Poisonings and overdoses in the
intensive care unit: general and specific manage-
ment issues. Crit Care Med 2003;31:2794–801.
This article provides a concise and well-written
review of current strategies for management of
common overdoses and poisonings in the critical
care setting.  Gastrointestinal decontamination
and methods for enhancing elimination of the
toxin are covered, and brief overviews are provided
for the most common poisonings encountered in
the ICU.
Vasoactive Agents
Hollenberg SM,  Ahrens TS, Annan D, et al.
Practice parameters for hemodynamic support of
sepsis in adult patients: 2004 update. Crit Care
Med 2004;32:1928–48.
This recent article is an evidence-based review
by the American College of Critical Care Medicine
of the literature related to hemodynamic support
in patients with sepsis.  Specific recommen-
dations are provided for monitoring parameters
and end points for therapy.  Areas discussed
include fluid resuscitation, vasopressor therapy,
and inotropic therapy for adult patients with
sepsis.
Dellinger RP. Cardiovascular management of
septic shock. Crit Care Med 2003;31:946–55.
This concise, well-written review provides an
overview of the management of septic shock.
Principles of fluid resuscitation, vasopressor and
inotropic drug treatment, and the role of
vasopressin are covered.  A one-page flow
diagram of management decisions based on
hemodynamic and clinical response is also
provided.
Dünser MW, Mayr AJ, Ulmer H, et al. Arginine
vasopressin in advanced vasodilatory shock: a
prospective, randomized, controlled study.
Circulation 2003;107:2313–19.
The increased use of vasopressin in the
management of vasodilatory shock is based
primarily on small case series, case reports, and
very small prospective studies.  This study is the
largest prospective, randomized, controlled study
of vasopressin published to date.  Forty-eight
patients with vasodilatory shock were ran-
domized to receive arginine vasopressin at 4
U/hour (0.067 U/min) in addition to norepi-
nephrine or continued norepinephrine therapy.
The vasodilatory shock in all patients was due to
postcardiotomy syndrome (41.6%), systemic
inflammatory response syndrome (29.2%), or
sepsis (29.2%).  In addition, patients remained
hypotensive (mean arterial pressure < 70 mm
Hg) despite adequate fluid resuscitation and
required norepinephrine administered at more
than 0.5 µg/kg/minute.  In the arginine vaso-
pressin group, heart rate decreased significantly;
mean arterial pressure increased and remained
significantly higher; and cardiac index, stroke
volume index, and left ventricular stroke work
index were increased compared with the
norepinephrine group.  Norepinephrine require-
ments were significantly lower in the arginine
vasopressin group.  New-onset tachycardic atrial
fibrillation occurred in two (8.3%) patients in the
arginine vasopressin group, compared with 14
(54.3%) patients in the norepinephrine group
(p<0.001).  Regional partial pressure of carbon
dioxide (PCO2) tension and PCO2 gap, as
measured by gastric tonometry, were significantly
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lower in the arginine vasopressin group.  This
suggests improved gastrointestinal perfusion in
the intervention group.  Mortality in the ICU was
70% in both study groups.  Overall, arginine
vasopressin was safe and effective for manage-
ment of norepinephrine-dependent vasodilatory
shock and led to reduced norepinephrine dosage
requirements, improved global and regional
hemodynamics, and fewer tachyarrhythmias.
(Class I)
Holmes CL, Walley KR. Bad medicine: low-dose
dopamine in the ICU. Chest 2003;123:1266–75.
The authors reviewed the 30-year history of
low-dose dopamine treatment in the ICU.  Based
on the collective evidence, they concluded that
this therapy does not have a beneficial effect in
critically ill patients with oliguria.  In addition,
substantial evidence indicates that low-dose
dopamine may have significant detrimental
effects.  The authors concluded that there is no
justification for the use of low-dose dopamine in
treating critically ill patients.
Martin C, Viviand X, Leone M, Thirion X. Effect
of norepinephrine on the outcome of septic
shock. Crit Care Med 2000;28:2758–65.
This prospective, cohort, observational study
was designed to identify factors associated with
outcome in 97 patients treated for septic shock.
Nineteen clinical, biologic, and hemodynamic
variables were collected during the first 48–72
hours of treatment.  Stepwise logistic regression
analysis was used to identify variables that were
independently and significantly associated with
outcome.  The primary outcome variable was
hospital mortality, which was 73% in this cohort.
Five factors were significantly associated with
outcome.  Lactic acidosis, multiple organ failure,
pneumonia, and oliguria were associated with an
increased risk of death, and norepinephrine as a
component of hemodynamic management was
associated with reduced risk of death (relative
risk ratio 0.68, 95% CI 0.54–0.87) when
compared with high-dose dopamine or
epinephrine.  Currently, no mortality outcome
data from prospective randomized trials evaluate
the hemodynamic management of septic shock.
This observational study is the only study
reporting that mortality outcome may be affected
by the choice of vasopressors.  The study was
limited by its observational design and relatively
small sample.  (Class II)
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